Life Science News

Gilead Sciences Again Named to Dow Jones Sustainability World Index

DJSI World Highlights the Most Sustainable Companies Around the World Based on Corporate Sustainability Assessment –

– Ranking Reflects Gilead's Ongoing Commitment to Corporate Responsibility –

Gilead Sciences, Inc. (Nasdaq: GILD) today announced the company has once again been recognized as one of the most sustainable pharmaceutical companies according to the Dow Jones Sustainability World Index (DJSI World). This ranking is based on an in-depth analysis of Gilead's sustainability performance and highlights the company's longstanding sustainable business practices and transparency on environmental, social and governance (ESG) issues.

"We are very pleased to receive this recognition once again, as a reflection of our commitment to patients, local communities, society and the planet," said Daniel O'Day, Chairman and Chief Executive Officer, Gilead Sciences. "Corporate responsibility is inherent in everything Gilead does, as we work toward our vision of making the world a healthier place for all people."

Gilead's ESG strategy aims to position the company as an employer of choice that delivers shareholder value in a responsible manner. Examples of Gilead's commitment to ESG include:

  • Expanding health equity around the world through programs that promote health system sustainability, strengthen infrastructure and provide education and financial support
  • Increasing access to medicines in low- and lower-middle income countries, including royalty-free voluntary licensing for Gilead's antiviral treatment for COVID-19
  • Creating an inclusive workplace that is representative of the diverse communities the company serves
  • Continuing to evolve the company's environmental sustainability program and reducing greenhouse gas emissions, minimizing waste generation and using resources efficiently

The DJSI World applies a transparent, rules-based constituent selection process based on the companies' S&P Global ESG Score resulting from the annual S&P Global Corporate Sustainability Assessment (CSA). The CSA consists of a rigorous questionnaire assessing both public and non-public data submitted by participating companies. This year, more than 10,000 publicly traded companies were invited to participate in the S&P Global CSA.

Details on Gilead's ESG commitments, goals and progress can be found in the company's Year in Review , which is based on internationally recognized guidelines from the Global Reporting Initiative, the Sustainability Accounting Standards Board, the Taskforce on Climate Related Financial Disclosures and the United Nations Sustainable Development Goals. Learn more about Gilead's commitment to ESG and corporate responsibility at https://www.gilead.com/purpose/sustainability .

About Gilead Sciences

Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, inflammation and cancer. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, California.

Gilead and the Gilead logo are registered trademarks of Gilead Sciences, Inc., or its related companies.

For more information about Gilead, please visit the company's website at www.gilead.com , follow Gilead on Twitter (@Gilead Sciences) or call Gilead Public Affairs at 1-800- GILEAD-5 or 1-650-574-3000.

Jacquie Ross, Investors
Investor_relations@gilead.com

Hayley Home, Media
Public_affairs@gilead.com

News Provided by Business Wire via QuoteMedia

GILD
The Conversation (0)
abigail echo-hawk

CORRECTION: Contakt World Becomes Data Partner for Health Equity Tracker Project to Improve the Collection of De-Identified Racial & Ethnic Minority Data Using Smart Health RM, Engagency, and Future Services

Enables Contakt World mission to improve health equity and reduce disparities in the fight against Covid-19 and all diseases via award-winning SaaS platform

This document corrects and updates the final paragraph in the body of this news release. No other changes were required in this release.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
"investingnews.com"

Contakt World Becomes Data Partner for Health Equity Tracker Project to Improve the Collection of De-Identified Racial & Ethnic Minority Data Using Smart Health RM, Engagency, and Future Services

Enables Contakt World mission to improve health equity and reduce disparities in the fight against Covid-19 and all diseases via award-winning SaaS platform

  • Covid-19 has proven to be the "great revealer" of disparities in healthcare

  • Contakt World (CSE: HELP) and Satcher Health Leadership Institute, Morehouse School of Medicine executed a strategic collaboration in October 2020
  • Health Equity Tracker, supported by Google.org, Gilead Sciences (Nasdaq: GILD), Annie E. Casey Foundation, and CDC Foundation, is now operational
  • Contakt World's SaaS Platform, Smart Health RM, will help drive de-identified data to Health Equity Tracker to improve health equity and reduce disparities of care

Contakt World Technologies Corp. (CSE: HELP) (OTC: TLOOF) (FSE: B2I0) (the "Company" or "Contakt World") today announced its agreement in principle with Satcher Health Leadership Institute, Morehouse School of Medicine ("SHLI") to help collect de-identified demographic data for the Health Equity Tracker Project through Smart Health RM and other products and services provided by Contakt World like Engagency. This updates the previously announced collaboration between Contakt World and SHLI now that Health Equity Tracker is operational.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less

HOOKIPA Advances HIV and HBV Vaccine Research with Gilead

HOOKIPA Pharma (NASDAQ:HOOK) announced that it has made progress in its collaboration with Gilead Sciences (NASDAQ:GILD) for arenavirus-based therapeutics intended to support cures for chronic Hepatitis B virus (HBV) and human immunodeficiency virus (HIV) infections.

As quoted in the press release:

Keep reading...Show less

Kite Announces Initial Results From a Phase 1 Study of T Cell Receptor (TCR) Cell Therapy in HPV-16-Positive Solid Tumors

Kite, a Gilead Company (Nasdaq: GILD), today announced results from an ongoing Phase 1 study conducted by the National Cancer Institute (NCI) showing that clinical responses were observed with investigational T cell receptor (TCR) cell therapy targeting human papillomavirus type 16 (HPV-16) E7 in solid tumor cancers caused by HPV. These findings were presented today in a poster session at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago (Abstract #3043).

As quoted in the press release:

Keep reading...Show less

Gilead Sciences Announces Promotion in Oncology Division

Gilead Sciences (NASDAQ:GILD) shared the promotion of Dr. Alessandro Riva to executive vice president of Oncology Therapeutics, with responsibility for Gilead’s hematology and oncology programs.
As quoted in the press release:

Dr. Riva will become a member of Gilead’s senior leadership team.
Dr. Riva joined Gilead in January 2017 as Senior Vice President, Hematology and Oncology Therapeutic Area Head. He has been instrumental in expanding Gilead’s oncology program with the recent acquisition of Kite Pharma, establishing the company as a leader in the field of cellular therapy. He has also guided the strategy and development of Gilead’s broader oncology pipeline during his tenure.

Keep reading...Show less

Aptose Reports Results for the Fourth Quarter and Full Year 2022

─ APTIVATE Expansion Trial of Tuspetinib as Single Agent in Relapsed/Refractory AML Patients is Up and Running; Initiated Enrollment of Combination Treatment Arm with Venetoclax ─

─ RAS Mutated AML Clinically Sensitive to Tuspetinib ─

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Sirona Biochem Announces Debenture Financing

Sirona Biochem Announces Debenture Financing

Sirona Biochem Corp . (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) (" Sirona " or the " Company ") is pleased to announce a non-brokered private placement offering of unsecured, convertible debentures (the " Convertible Debentures "). The Company is offering Convertible Debentures units (the " Debenture Units ") at a price of $1,000 per Debenture Unit for aggregate gross proceeds of up to $1,500,000 (the " Offering ").

Each Debenture Unit will have a face value of (the " Face Value ") of $1,120, consisting of $1,000 in principal (the " Principal ") and $120 in prepaid interest (the " Prepaid Interest "). The Principal of the Debenture Units will accrue interest at a rate of 12% per annum, which accrued interest (" Accrued Interest ") will be paid semi-annually, in arrears. The Company will pay the Prepaid Interest and Accrued Interest in cash or, subject to TSX Venture Exchange (" TSXV ") acceptance, may elect to satisfy payment in kind by issuing Shares (" Interest Shares "). In the event of payment in kind, the number of Interest Shares due will be calculated using a conversion price (the " Interest Conversion Price ") equal to, subject to acceptance by the TSXV, the maximum Discounted Market Price (as defined in TSXV policies) on the applicable payment due date.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

AbbVie Advances Upadacitinib to Phase 3 Clinical Trials in Systemic Lupus Erythematosus

  • Results of the M19-130 (SLEek) Phase 2 trial of upadacitinib given alone or as a combination therapy (ABBV-599) met the primary endpoint of systemic lupus erythematosus (SLE) Responder Index (SRI-4) and steroid dose less than or equal to 10 mg prednisone equivalent once per day at week 24 in patients with moderately to severely active SLE 1 , 2
  • No new safety signals were identified with upadacitinib, and a similar safety profile was observed for the combination therapy (ABBV-599) as for treatment with upadacitinib alone 2, 3 , 4 , 5 , 6 , 7
  • SLE is a complex autoimmune disorder in which the body's immune system attacks healthy tissue of the musculoskeletal system, skin, kidneys, lungs and other critical organs, leading to symptoms such as fatigue, joint pain and impaired function. 8 , 9

ABBVie (NYSE: ABBV) today announced topline results from a Phase 2 study of upadacitinib (RINVOQ ® 30 mg) given alone or as combination therapy (ABBV-599) with a Bruton's Tyrosine Kinase inhibitor (elsubrutinib, 60 mg), once daily in patients with moderately to severely active systemic lupus erythematosus (SLE). 1 The SLEek study met the primary endpoint of SLE Responder Index (SRI-4) and steroid dose less than or equal to 10 mg prednisone equivalent once per day at week 24 in the upadacitinib 30 mg group. 1,2 Based on the results, ABBVie is advancing its clinical program of upadacitinib in SLE to Phase 3.

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

Risankizumab Achieves Primary and All Secondary Endpoints in Phase 3 Induction Study in Patients With Ulcerative Colitis

  • A significantly higher proportion of patients with moderately to severely active ulcerative colitis treated with risankizumab achieved the primary endpoint of clinical remission a (per Adapted Mayo Score) compared to placebo at week 12 in the Phase 3 INSPIRE induction study
  • All secondary endpoints, including clinical, endoscopic and histologic outcomes, were met
  • Safety results in this study were consistent with the known safety profile of risankizumab, with no new safety risks observed 1
  • Building on AbbVie's growing gastroenterology portfolio, risankizumab is an IL-23 inhibitor being evaluated as a treatment for adults with moderate to severe ulcerative colitis and approved for Crohn's disease, psoriatic arthritis, and psoriasis 1

ABBVie (NYSE: ABBV) today announced positive top-line results from INSPIRE, a Phase 3 induction study, showing risankizumab (SKYRIZI ® ,1200 mg intravenous [IV], at weeks 0, 4 and 8) met the primary endpoint of clinical remission (per Adapted Mayo Score) at week 12, as well as all secondary endpoints in adult patients with moderately to severely active ulcerative colitis. 1 In the study, 20.3% of patients receiving risankizumab achieved clinical remission compared to 6.2% of patients receiving placebo (p

"Our commitment to people living with gastroenterological conditions continues to grow," said Roopal Thakkar , M.D., senior vice president, development, regulatory affairs and chief medical officer, AbbVie. "These encouraging results help support the potential risankizumab has to improve clinical, endoscopic and histologic outcomes in patients with ulcerative colitis."

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

Gilead Sciences Announces $3 Million in Grant Funding to Eight Organizations Addressing HIV Disparities in Rural U.S. Communities

Funding Will Reach Under-Resourced Communities Impacted by the HIV Epidemic as Part of Gilead's Zeroing In™: Ending the HIV Epidemic Grant Program –

Gilead Sciences, Inc. (Nasdaq: GILD) today announced it is providing a total of $3 million in grant funding to eight organizations to provide services to communities disproportionately impacted by HIV in rural areas in the United States. My Brother's Keeper, based in Ridgeland, Mississippi, will provide technical assistance and capacity building to the organizations funded through this initiative. These grants are part of Gilead's ongoing Zeroing In™ program to help end the HIV epidemic by supporting organizations working to improve the overall health and wellness of communities most impacted by the HIV epidemic.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

AbbVie Provides Regulatory Update on ABBV-951 New Drug Application

ABBVie (NYSE: ABBV) today announced it received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) for the New Drug Application (NDA) for ABBV-951 (foscarbidopafoslevodopa) for the treatment of motor fluctuations in adults with advanced Parkinson's disease.

In its letter, the FDA requested additional information about the device (pump) as part of the NDA review. The CRL does not request that AbbVie conduct additional efficacy and safety trials related to the drug. AbbVie plans to resubmit the NDA as soon as possible.

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×